Perkins Capital Management’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.61M Sell
110,040
-22,310
-17% -$215K 1.21% 21
2026
Q1
$982K Sell
132,350
-9,500
-7% -$100K 0.92% 31
2025
Q4
$1.67M Buy
141,850
+5,000
+4% +$53.9K 1.32% 20
2025
Q3
$1.06M Sell
136,850
-31,100
-19% -$218K 0.93% 35
2025
Q2
$1.23M Sell
167,950
-11,600
-6% -$93.6K 1.23% 26
2025
Q1
$1.7M Buy
179,550
+600
+0.3% +$7.49K 1.8% 15
2024
Q4
$2.95M Sell
178,950
-1,850
-1% -$28.7K 2.62% 10
2024
Q3
$2.67M Sell
180,800
-6,500
-3% -$102K 2.5% 10
2024
Q2
$2.6M Sell
187,300
-5,900
-3% -$83.6K 2.45% 8
2024
Q1
$3.04M Hold
193,200
2.53% 8
2023
Q4
$3.13M Sell
193,200
-750
-0.4% -$12.3K 2.67% 8
2023
Q3
$2.39M Sell
193,950
-2,550
-1% -$37.9K 2.37% 11
2023
Q2
$3.16M Sell
196,500
-500
-0.3% -$8.24K 2.75% 5
2023
Q1
$3.43M Sell
197,000
-700
-0.4% -$9.97K 3.23% 6
2022
Q4
$1.83M Buy
197,700
+2,150
+1% +$20K 1.93% 17
2022
Q3
$1.68M Sell
195,550
-7,000
-3% -$69.5K 1.88% 16
2022
Q2
$1.65M Buy
202,550
+50,000
+33% +$477K 1.71% 20
2022
Q1
$1.85M Sell
152,550
-3,000
-2% -$63.1K 1.52% 26
2021
Q4
$5.31M Sell
155,550
-2,200
-1% -$86.2K 3.58% 4
2021
Q3
$7.61M Sell
157,750
-550
-0.3% -$25.5K 4.71% 2
2021
Q2
$7.15M Sell
158,300
-2,500
-2% -$111K 4.06% 3
2021
Q1
$7.75M Sell
160,800
-20,450
-11% -$1.06M 4.48% 2
2020
Q4
$9.76M Sell
181,250
-18,275
-9% -$826K 6.38% 1
2020
Q3
$7.36M Buy
+199,525
New +$7.42M 6.76% 1
2020
Q1
$6.48M Sell
234,850
-17,650
-7% -$529K 7.83% 1
2019
Q4
$7.39M Sell
252,500
-9,800
-4% -$233K 6.62% 1
2019
Q3
$5.01M Sell
262,300
-17,400
-6% -$408K 4.32% 2
2019
Q2
$6.14M Buy
279,700
+15,050
+6% +$330K 4.3% 3
2019
Q1
$5.42M Sell
264,650
-16,850
-6% -$293K 3.57% 4
2018
Q4
$3.55M Sell
281,500
-2,400
-0.8% -$35.8K 2.75% 5
2018
Q3
$4.36M Sell
283,900
-5,900
-2% -$81.5K 2.62% 5
2018
Q2
$3.8M Sell
289,800
-3,050
-1% -$33.6K 2.72% 4
2018
Q1
$2.39M Sell
292,850
-5,000
-2% -$40.5K 2.15% 5
2017
Q4
$2.64M Sell
297,850
-10,450
-3% -$96.4K 2.54% 4
2017
Q3
$3.43M Sell
308,300
-500
-0.2% -$4.87K 3.59% 4
2017
Q2
$2.77M Sell
308,800
-211,475
-41% -$1.68M 3.07% 6
2017
Q1
$4.11M Sell
520,275
-9,900
-2% -$80.6K 4.24% 2
2016
Q4
$4.54M Sell
530,175
-125,625
-19% -$1.08M 4.98% 3
2016
Q3
$5.39M Sell
655,800
-17,232
-3% -$145K 5.39% 2
2016
Q2
$5.41M Sell
673,032
-24,450
-4% -$196K 6.2% 1
2016
Q1
$4.7M Sell
697,482
-6,950
-1% -$45.7K 5.88% 2
2015
Q4
$5.54M Sell
704,432
-89,580
-11% -$656K 5.95% 2
2015
Q3
$4.55M Sell
794,012
-2,918
-0.4% -$18.1K 5.06% 2
2015
Q2
$4.31M Sell
796,930
-12,250
-2% -$63.2K 3.79% 3
2015
Q1
$3.78M Sell
809,180
-7,500
-0.9% -$32.6K 3.17% 4
2014
Q4
$3.41M Buy
816,680
+1,700
+0.2% +$7.81K 2.92% 3
2014
Q3
$4.25M Buy
814,980
+25,000
+3% +$128K 3.59% 3
2014
Q2
$2.62M Hold
789,980
1.85% 11
2014
Q1
$2.74M Buy
789,980
+31,300
+4% +$117K 1.92% 8
2013
Q4
$2.75M Buy
758,680
+191,073
+34% +$663K 1.85% 10
2013
Q3
$1.7M Buy
567,607
+194,227
+52% +$547K 1.22% 28
2013
Q2
$1.49M Buy
+373,380
New +$1.42M 1.18% 32

Other funds holding NEO

Perkins Capital Management's NEO Position: Q2 2026 in Review

Perkins Capital Management reduced its NeoGenomics (NEO) stake by 17% in Q2 2026, selling an estimated $215K and leaving 110,040 shares worth $1.61M. The position accounts for 1.21% of the portfolio, ranked #21.

Perkins Capital Management first reported a position in NEO in Q2 2013 and has held it in 52 quarters since. The position peaked at $9.76M in Q4 2020. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • Perkins Capital Management held 110,040 shares of NeoGenomics worth $1.61M as of Q2 2026.
  • Perkins Capital Management sold 22,310 NeoGenomics shares in Q2 2026, an estimated $215K.
  • NeoGenomics made up 1.21% of Perkins Capital Management's portfolio in Q2 2026, its #21 holding.
  • Perkins Capital Management first reported a position in NeoGenomics in Q2 2013 and has held it in 52 quarters since.
  • Perkins Capital Management's NeoGenomics position peaked at $9.76M in Q4 2020.
  • 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on Perkins Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.